{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:02Z","timestamp":1790369942678,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma has long been considered incurable; however, advances in therapy have markedly improved outcomes, with a growing proportion of patients achieving sustained remissions suggestive of cure. Minimal (or measurable) residual disease (MRD) has emerged as the most informative biomarker for assessing depth of response and predicting clinical outcomes. Evidence consistently demonstrates that MRD negativity surpasses conventional complete response in prognostic value across disease settings, treatment regimens, and risk groups. Furthermore, MRD has shown potential as a surrogate endpoint for clinical trials and as a tool to guide therapeutic decisions, including treatment intensification, de-escalation, and maintenance strategies. Emerging data also support its relevance in the context of immunotherapy and non\u2013bone marrow-based assessment approaches. Collectively, these findings position MRD as a central component in the evolution toward more precise and individualized management of multiple myeloma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000846","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:03Z","timestamp":1790366463000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-0992","authenticated-orcid":false,"given":"Luis-Esteban","family":"Tamariz-Amador","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manubens","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lasa","sequence":"additional","affiliation":[{"name":"Cima Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Cancer Center Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Cima Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Cancer Center Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Cima Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Cancer Center Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"36","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"New Engl J Med"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of post-consolidation minimal residual disease rates by multiparametric flow cytometry and next-generation sequencing in CASSIOPEIA","volume":"19","author":"Avet-Loiseau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1200\/EDBK_159088","article-title":"Minimal residual disease by next-generation sequencing: pros and cons","author":"Avet-Loiseau","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Bai","year":"2018","journal-title":"Br J Haematol"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"R20-20260925","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","article-title":"Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial","volume":"42","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J Clin Oncol"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R23-20260925","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/S2152-2650(24)01665-3","article-title":"MM-329 daratumumab + bortezomib\/lenalidomide\/dexamethasone (D-VRd) in transplant-eligible (TE) patients with newly diagnosed myeloma (NDMM): analysis of the phase 3 PERSEUS study based on high-risk cytogenetic abnormalities (HRCAs)","volume":"24","author":"Dimopoulos","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am J Hematol"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.2025031952","article-title":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy","volume":"147","author":"Bal","year":"2026","journal-title":"Blood Journal"},{"key":"R30-20260925","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1016\/S2152-2650(25)04013-3","article-title":"Patient-reported outcomes (PROs) and safety in patients (Pts) with NDMM achieving MRD negativity and \u2265CR (MRDneg) in the phase 3 PERSEUS and CEPHEUS trials","volume":"25","author":"San-Miguel","year":"2025","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"Supplement 1","key":"R32-20260925","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2024-200871","article-title":"Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: analysis of minimal residual disease in the cepheus trial","volume":"144","author":"Zweegman","year":"2024","journal-title":"Blood"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"New Engl J Med"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2017.73.1331","article-title":"Minimal residual disease negativity is a new end point of myeloma therapy","volume":"35","author":"Harousseau","year":"2017","journal-title":"J Clin Oncol"},{"key":"R36-20260925","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease\u2013based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"R38-20260925","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"R42-20260925","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"key":"R43-20260925","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"R44-20260925","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R45-20260925","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41409-018-0245-y","article-title":"Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma","volume":"53","author":"Moor","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R46-20260925","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J"},{"key":"R47-20260925","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1002\/hem3.63","article-title":"Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant","volume":"8","author":"Tembhare","year":"2024","journal-title":"Hemasphere"},{"key":"R48-20260925","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable residual disease and decision-making in multiple myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Supplement 1","key":"R49-20260925","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2024-209748","article-title":"Clinical value of peripheral residual disease (PRD) and measurable residual disease (mrd) in newly diagnosed elderly patients in the GEM2017FIT trial","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"R50-20260925","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"key":"R51-20260925","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"key":"R52-20260925","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.3324\/haematol.2024.285742","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial","volume":"109","author":"Puig","year":"2024","journal-title":"Haematologica"},{"key":"R53-20260925","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"R54-20260925","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"R55-20260925","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"key":"R56-20260925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"key":"R57-20260925","doi-asserted-by":"crossref","first-page":"e063037","DOI":"10.1136\/bmjopen-2022-063037","article-title":"Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial","volume":"12","author":"Royle","year":"2022","journal-title":"BMJ Open"},{"key":"R58-20260925","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"R59-20260925","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"key":"R60-20260925","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D\u2019Agostino","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"R61-20260925","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood-2023-189022","article-title":"Will survival improve by treating multiple myeloma patients at MRD relapse? The remnant study","volume":"142","author":"Askeland","year":"2023","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:11Z","timestamp":1790366471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000846","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}